Liraglutide is a GLP-1 analog, which is resistant to degradation. Phase III trials have demonstrated that liraglutide effectively controls glucose levels, while reducing bodyweight.

Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

In diabetes, injectable GLP-1 analog Ozempic (patent 2032) looks best-in-class over Lilly's Trulicity, and oral Rybelsus (patent 2032) expands reach into the oral diabetes treatment market.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI launches shopping agent Operator; Etsy, eBay tick higher.

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 receptor agonist (GLP-1RA) could see their liver health improve with the addition ...